Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T
BCMA expression did not correlate with clinical response.
ASH 2018
JCARH125 CAR-T “Highly Active” in Relapsed/Refractory Multiple Myeloma
Patients saw a deepening of responses over time.
Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma
Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.
Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted
AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.
Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM
Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.
REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019
The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.
Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL
Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure
Drug Sensitivity Is Genotype-Dependent: Study
Genetically defined mouse models of AEL could help researchers find novel treatment approaches.
New Standard of Care in CLL Proposed for Older Patients
Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...